ImmuCell Corporation (NASDAQ:ICCC) Sees Large Drop in Short Interest

Posted by George Bondi on May 2nd, 2026

ImmuCell Corporation (NASDAQ:ICCC – Get Free Report) was the recipient of a large decline in short interest in the month of April. As of April 15th, there was short interest totaling 27,130 shares, a decline of 20.8% from the March 31st total of 34,248 shares. Approximately 0.3% of the company’s shares are short sold. Based on an average trading volume of 33,432 shares, the short-interest ratio is currently 0.8 days.

Hedge Funds Weigh In On ImmuCell

A number of institutional investors have recently added to or reduced their stakes in ICCC. Geode Capital Management LLC raised its stake in shares of ImmuCell by 4.2% in the 2nd quarter. Geode Capital Management LLC now owns 71,852 shares of the biotechnology company’s stock valued at $500,000 after purchasing an additional 2,907 shares in the last quarter. Mesirow Financial Investment Management Inc. raised its stake in shares of ImmuCell by 199.6% in the 4th quarter. Mesirow Financial Investment Management Inc. now owns 36,481 shares of the biotechnology company’s stock valued at $224,000 after purchasing an additional 24,303 shares in the last quarter. Finally, Steadtrust LLC raised its stake in shares of ImmuCell by 79.1% in the 4th quarter. Steadtrust LLC now owns 56,770 shares of the biotechnology company’s stock valued at $349,000 after purchasing an additional 25,070 shares in the last quarter. Institutional investors and hedge funds own 13.47% of the company’s stock.

ImmuCell Stock Up 3.2%

ImmuCell stock traded up $0.27 during trading on Friday, reaching $8.73. 18,043 shares of the company’s stock were exchanged, compared to its average volume of 27,300. The company’s 50-day moving average is $6.89 and its two-hundred day moving average is $6.31. The company has a debt-to-equity ratio of 0.28, a quick ratio of 1.93 and a current ratio of 4.26. ImmuCell has a 52-week low of $4.52 and a 52-week high of $8.82. The firm has a market cap of $78.98 million, a price-to-earnings ratio of -79.36 and a beta of 0.30.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings cut shares of ImmuCell from a “hold (c-)” rating to a “sell (d-)” rating in a research note on Monday, April 6th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has an average rating of “Sell”.

Read Our Latest Stock Report on ImmuCell

About ImmuCell

(Get Free Report)

ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.